文献速递眼底病与葡萄膜炎

Wnt通路在VEGF/抗VEGF调控内皮细胞屏障中的作用

The Role of the Wnt Pathway in VEGF/Anti-VEGF-Dependent Control of the Endothelial Cell Barrier.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2021-01-01

该研究在高糖处理的原代人视网膜内皮细胞中,探讨Wnt通路对VEGF/抗VEGF介导的内皮细胞通透性调控的贡献。VEGF/抗VEGF改变多种Wnt通路基因表达,激活Wnt通路可抑制VEGF诱导的屏障松弛,但不影响抗VEGF的屏障恢复作用。提示LiCl等FDA批准药物或可作为抗VEGF治疗的辅助。

要点

  • VEGF/抗VEGF调控多个Wnt通路基因表达,部分变化与屏障功能改变时间对应。
  • 药物和分子激活Wnt通路不影响基础通透性,但抑制VEGF诱导的屏障松弛。
  • 抗VEGF恢复屏障功能不受Wnt通路激活影响。

核心结论

  • VEGF/抗VEGF涉及多个Wnt通路成员,激活Wnt通路通过减弱VEGF诱导的松弛来强化内皮屏障。

研究设计与样本

  • 高糖处理的原代人视网膜内皮细胞(HRECs)暴露于VEGF或先VEGF后抗VEGF,用RNAseq和qRT-PCR检测基因表达,ECIS监测通透性。
  • 通过LiCl处理和过表达组成性激活β-catenin激活Wnt通路,用TCF/LEF驱动报告基因监测β-catenin依赖转录活性。

主要发现

  • VEGF/抗VEGF改变编码多个Wnt通路成员的基因表达,其中一部分基因的表达变化在时间上与屏障功能改变相对应。
  • 药理学和分子激活Wnt通路对基础通透性无影响,但抑制VEGF诱导的松弛。
  • 抗VEGF介导的屏障功能恢复不受Wnt通路激活影响。

临床怎么用

  • LiCl等FDA批准药物或可作为抗VEGF治疗的辅助,用于糖尿病视网膜病变等致盲性疾病患者。

局限性

  • 研究仅在高糖处理的HRECs中进行,结论需进一步体内验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Investigate the contribution of the Wnt pathway to vascular endothelial growth factor (VEGF)/anti-VEGF-mediated control of endothelial cell permeability. METHODS: High glucose-treated primary human retinal endothelial cells (HRECs) were exposed to either VEGF, or VEGF and then anti-VEGF. Changes in gene expression were assayed by RNAseq and qRT-PCR. Permeability was monitored by electrical cell-substrate impedance sensing (ECIS). Approaches to activate the Wnt pathway included treatment with LiCl and overexpression of constitutively activated β-catenin. β-catenin-dependent transcriptional activity was monitored in HRECs stably expressing a TCF/LEF-driven reporter. RESULTS: VEGF/anti-VEGF altered expression of genes encoding many members of the Wnt pathway. A subset of these genes was regulated in a way that is likely to contribute to control of the endothelial cell barrier. Namely, the VEGF-induced alteration of expression of such genes was reversed by anti-VEGF, and such adjustments occurred at times corresponding to changes in barrier function. While pharmacological and molecular approaches to activate the Wnt pathway had no effect on basal permeability, they suppressed VEGF-induced relaxation. Furthermore, anti-VEGF-mediated restoration of barrier function was unaffected by activation of the Wnt pathway. CONCLUSIONS: VEGF/anti-VEGF engages multiple members of the Wnt pathway, and activating this pathway enforces the endothelial barrier by attenuating VEGF-induced relaxation. These data suggest that FDA-approved agents such as LiCl may be an adjuvant to anti-VEGF therapy for patients afflicted with blinding conditions including diabetic retinopathy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Li Y, Baccouche B, Olayinka O, et al. The Role of the Wnt Pathway in VEGF/Anti-VEGF-Dependent Control of the Endothelial Cell Barrier. Invest Ophthalmol Vis Sci. 2021. PMID: 34542556. doi:10.1167/iovs.62.12.17

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。